Influenza A benfits biotech firms

Published: 2009-08-20 06:59:00

Updated: 2009-08-20 06:59:00

As H1N1 influenza claimed the lives of two Koreans over the weekend, shares of biotech companies surged on August 18, although the benchmark KOSPI headed down.

Green Cross Corp., the only Korean company with a facility for manufacturing vaccines for the flu, jumped by more than 14 percent from...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK